Redacid

Redacid is a branded herbal phytopharmaceutical developed by Dexa Group/DLBS that contains DLBS2411, a standardized bioactive fraction derived from the bark of Cinnamomum burmannii, indicated for hyperacidity, dyspepsia, peptic ulcer disease, and gastroesophageal reflux disease. DLBS2411 acts primarily as a gastric proton pump inhibitor by competitively inhibiting the H+/K+-ATPase in parietal cells and downregulating H+/K+-ATPase mRNA expression, thereby suppressing gastric acid secretion, while also exerting mucoprotective and antioxidant effects that enhance gastric and colonic mucus synthesis and mucosal blood flow via NF-κB–mediated upregulation of MUC5AC, COX-2, and nitric oxide. Redacid is formulated as oral caplets (and oral liquid in some materials) and has obtained Indonesian BPOM phytopharmaca marketing authorization as an Indonesia Indigenous Modern Medicine.

Brand names

Redacid

Other names

Cinnamomum burmannii bioactive fractionIndonesian cinnamon bioactive fraction